# The Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis (FRMC)

> **NCT00041704** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 19 (actual)

## Conditions studied

- Candidiasis

## Interventions

- **DRUG:** Anidulafungin, VER002

## Key facts

- **NCT ID:** NCT00041704
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-08
- **Primary completion:** —
- **Final completion:** 2004-08
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2008-10-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00041704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00041704, "The Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis (FRMC)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00041704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*